Erasca (ERAS) Common Equity (2020 - 2026)
Erasca's (ERAS) quarterly Common Equity came in at $393.5 million in Q1 2026, down 1.5% YoY from $399.5 million in Q1 2025, and up 21.02% on a QoQ basis from $325.2 million in Q4 2025.
Erasca (ERAS) Common Equity (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Common Equity data on file, last reported at $393.5 million in Q1 2026.
- Quarterly Common Equity fell 1.5% year-over-year to $393.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $393.5 million (down 1.5% YoY) and the FY2025 annual result came in at $325.2 million, down 23.22% from the prior year.
- Common Equity climbed to $393.5 million in Q1 2026, from $325.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $451.1 million in Q2 2024 to a low of $288.4 million in Q1 2024.
- A 5-year average of $379.6 million and a median of $386.5 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity soared 428.54% — and 2024, when it decreased 25.37%.
- Tracing ERAS's Common Equity over 5 years: stood at $411.9 million in 2022, then decreased by 23.11% to $316.7 million in 2023, then surged by 33.73% to $423.5 million in 2024, then slipped by 23.22% to $325.2 million in 2025, then gained by 21.02% to $393.5 million in 2026.
- The last three Common Equity figures came in at $393.5 million (Q1 2026), $325.2 million (Q4 2025), and $347.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 361.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 361.87 Mn |
| Mar 31, 2026 | 393.53 Mn |
| Dec 31, 2025 | 325.17 Mn |
| Sep 30, 2025 | 347.89 Mn |
| Jun 30, 2025 | 372.26 Mn |
| Mar 31, 2025 | 399.50 Mn |
| Dec 31, 2024 | 423.50 Mn |
| Sep 30, 2024 | 450.04 Mn |
| Jun 30, 2024 | 451.09 Mn |
| Mar 31, 2024 | 288.41 Mn |
| Dec 31, 2023 | 316.69 Mn |
| Sep 30, 2023 | 338.98 Mn |
| Jun 30, 2023 | 362.71 Mn |
| Mar 31, 2023 | 386.45 Mn |
| Dec 31, 2022 | 411.85 Mn |
| Sep 30, 2022 | 365.32 Mn |
| Jun 30, 2022 | 395.07 Mn |
| Mar 31, 2022 | 424.66 Mn |
| Dec 31, 2021 | 456.53 Mn |
| Sep 30, 2021 | 482.99 Mn |